{
  "trial_id": "NCT03990363",
  "trial_group": "chronic kidney disease",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, race, baseline eGFR, baseline serum uric acid (sUA), baseline urinary albumin to creatinine ratio (UACR), history of chronic kidney disease (CKD) duration, background standard of care treatment for albuminuria, presence of type 2 diabetes mellitus (T2DM), use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs), use of sodium-glucose transport protein (SGLT2) inhibitors, blood pressure, body mass index (BMI), smoking status, baseline systolic blood pressure, baseline diastolic blood pressure, baseline liver function tests, baseline hemoglobin levels, baseline lipid profile.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Ethnicity (NIH/OMB)",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "baseline eGFR",
        "baseline serum uric acid (sUA)",
        "baseline urinary albumin to creatinine ratio (UACR)",
        "history of chronic kidney disease (CKD) duration",
        "background standard of care treatment for albuminuria",
        "presence of type 2 diabetes mellitus (T2DM)",
        "use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs)",
        "use of sodium-glucose transport protein (SGLT2) inhibitors",
        "blood pressure",
        "body mass index (BMI)",
        "smoking status",
        "baseline systolic blood pressure",
        "baseline diastolic blood pressure",
        "baseline liver function tests",
        "baseline hemoglobin levels",
        "baseline lipid profile"
      ]
    },
    "processed-gen-response": "Age, gender, race, baseline eGFR, baseline serum uric acid (sUA), baseline urinary albumin to creatinine ratio (UACR), history of chronic kidney disease (CKD) duration, background standard of care treatment for albuminuria, presence of type 2 diabetes mellitus (T2DM), use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs), use of sodium-glucose transport protein (SGLT2) inhibitors, blood pressure, body mass index (BMI), smoking status, baseline systolic blood pressure, baseline diastolic blood pressure, baseline liver function tests, baseline hemoglobin levels, baseline lipid profile."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Body Mass Index, Systolic Blood Pressure, Diastolic Blood Pressure, Serum Uric Acid, Estimated Glomerular Filtration Rate (eGFR), Urinary Albumin to Creatinine Ratio (uACR), Use of Angiotensin-Converting Enzyme Inhibitors (ACEi) or Angiotensin Receptor Blockers (ARBs), Use of Sodium-Glucose Transport Protein (SGLT2) Inhibitors,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Body Mass Index",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure",
        "Serum Uric Acid",
        "Estimated Glomerular Filtration Rate (eGFR)",
        "Urinary Albumin to Creatinine Ratio (uACR)",
        "Use of Angiotensin-Converting Enzyme Inhibitors (ACEi) or Angiotensin Receptor Blockers (ARBs)",
        "Use of Sodium-Glucose Transport Protein (SGLT2) Inhibitors"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Body Mass Index, Systolic Blood Pressure, Diastolic Blood Pressure, Serum Uric Acid, Estimated Glomerular Filtration Rate (eGFR), Urinary Albumin to Creatinine Ratio (uACR), Use of Angiotensin-Converting Enzyme Inhibitors (ACEi) or Angiotensin Receptor Blockers (ARBs), Use of Sodium-Glucose Transport Protein (SGLT2) Inhibitors"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Body Mass Index, Systolic Blood Pressure, Diastolic Blood Pressure, eGFR, Urinary Albumin to Creatinine Ratio, Serum Uric Acid, Diabetes Status, History of Cardiovascular Disease.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Body Mass Index",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure",
        "eGFR",
        "Urinary Albumin to Creatinine Ratio",
        "Serum Uric Acid",
        "Diabetes Status",
        "History of Cardiovascular Disease"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Body Mass Index, Systolic Blood Pressure, Diastolic Blood Pressure, eGFR, Urinary Albumin to Creatinine Ratio, Serum Uric Acid, Diabetes Status, History of Cardiovascular Disease."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, body mass index (BMI), systolic blood pressure, diastolic blood pressure, eGFR, serum uric acid (sUA), UACR, history of diabetes, history of hypertension, history of cardiovascular disease, smoking status, use of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, use of SGLT2 inhibitor, use of other medications for hyperuricaemia or albuminuria.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "body mass index (BMI)",
        "systolic blood pressure",
        "diastolic blood pressure",
        "eGFR",
        "serum uric acid (sUA)",
        "UACR",
        "history of diabetes",
        "history of hypertension",
        "history of cardiovascular disease",
        "smoking status",
        "use of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker",
        "use of SGLT2 inhibitor",
        "use of other medications for hyperuricaemia or albuminuria."
      ]
    },
    "processed-gen-response": "Age, sex, race, ethnicity, body mass index (BMI), systolic blood pressure, diastolic blood pressure, eGFR, serum uric acid (sUA), UACR, history of diabetes, history of hypertension, history of cardiovascular disease, smoking status, use of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, use of SGLT2 inhibitor, use of other medications for hyperuricaemia or albuminuria."
  }
}